Novo Nordisk expands job cuts to 1,300 as executives play down Lilly’s GLP-1 threat

1st November 2018 Uncategorised 0

First it was 400 R&D jobs, then about 250 positions in the U.S., and now Novo Nordisk says it will have cut about 1,300 employees by the end of 2018 to channel more resources toward newer drugs. Still, though, Eli Lilly’s recently lauded dual GIP/GLP-1 drug won’t be a threat in the near- to mid-term, executives said.

More: Novo Nordisk expands job cuts to 1,300 as executives play down Lilly’s GLP-1 threat
Source: fierce